Novadaq Technologies Inc.
TSX : NDQ

Novadaq Technologies Inc.

June 28, 2007 07:00 ET

Novadaq Announces Positive Experience With HELIOS Imaging

Provides Updates on LUNA and Milestones

TORONTO, ONTARIO--(Marketwire - June 28, 2007) -

Attention Business Editors:

Novadaq Technologies Inc. (TSX:NDQ), a developer of real-time medical imaging
systems and image guided therapies for the operating room, announced today
the results of the first clinical experience utilizing the HELIOS™
Fluorescence Imaging System. The study, presented by Michel C. Samson, MD,
interim Chairman, Department of Plastic Surgery at the Cleveland Clinic in
Florida, during the World Congress for Reconstructive Micro Surgery held in
Athens, Greece, June 24 - 26, confirmed that the use of intra-operative
real-time laser- assisted fluorescent imaging during free-flap breast
reconstructive surgery may result in improved intra-operative decision making
for surgeons performing complex plastic surgery procedures and ultimately
positively impact procedural outcomes for patients.

"Free tissue transfer is the most advanced and technically demanding form
of reconstructive plastic surgery. This technique is utilized when
reconstructing large defects created by trauma or neoplasm," said Dr. Michel
C. Samson.

"Adequate blood-flow, both to and from transferred tissue, is the most
critical component of this surgery. The ability to visually assess arterial
inflow and venous return, on a real time basis, during these complex
procedures assists us with intra-operative decision making and may ultimately
prove to impact outcomes", according to study co-author Martin Newman, M.D.,
also of Cleveland Clinic in Florida.."

Novadaq also reported that results from a pilot study of the use of the
LUNA™ Imaging System during surgery for kidney cancer were recently
presented at the 2007 annual meeting of the American Urological Association by
Dragan Golijanin, M.D, a urologist from the University of Rochester in
Rochester, NY. The study included detailed analysis of images obtained
utilizing the LUNA System during 10 kidney cancer surgeries. Results showed
that LUNA allowed surgeons to differentiate between healthy and malignant
cancerous tissue which enabled more precise removal of the malignant tissue
while preserving as much healthy tissue as possible. A critical factor in the
future health of cancer patients.

"We have significant published data that demonstrates the clinical value
of our lead product, the SPY System, during open heart cardiac surgery. Now
surgeons from other specialties are finding significant value in using our
technology during other complex operating room procedures," said Dr. Arun
Menawat, President and CEO of Novadaq. "While SPY and the complementary
surgical device for Trans Myocardial Revascularization (TMR) remain our short
term revenue drivers, we are delighted to see that these new applications can
significantly increase the potential opportunity for Novadaq."

About Novadaq Technologies

Novadaq Technologies Inc. (TSX:NDQ) develops and commercializes medical
imaging systems and real-time image guided therapies for use in the operating
room. Novadaq's proprietary imaging platform can be used to visualize blood
vessels, nerves and the lymphatic system during surgical procedures. Novadaq's
SPY® Imaging System, commercially available worldwide, enables cardiac
surgeons to visually assess coronary vasculature and bypass graft
functionality during the course of open-heart surgery. Novadaq's OPTTX®
System which received CE Mark approval in November 2006, is aimed at the
diagnosis, evaluation and treatment of wet Age-related Macular Degeneration
(AMD) by using the same core imaging technology that is used in the SPY
Imaging System. The HELIOS Imaging System, which received FDA clearance in
January 2007, is the first fluorescent imaging system available for use during
plastic reconstructive surgery allowing surgeons to evaluate pre- and
intra-operative blood flow, as well as post-surgery perfusion. Novadaq's LUNA
Imaging System is designed to enable surgeons to visualize nerve bundles
during the course of urological and neurological procedures. LUNA has been
granted a license for use by Health Canada. Novadaq is also the exclusive
United States distributor of PLC Medical's CO(2) HEART LASER™ System for
TMR (Trans-Myocardial Revascularization). Novadaq recently acquired a
comprehensive portfolio of minimally invasive native tissue fluorescence
imaging technology with the vision to expand the applications for this
technology in Novadaq's surgical markets. For more information, please visit
the company's website at www.novadaq.com.

Forward-Looking Information

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

For further information: visit our website at www.novadaq.com.

Contact Information